Business Context and Reporting Period
This Form 8-K, dated January 23, 2026, reports the completion of a material asset sale by DNA X, Inc. (formerly Sonim Technologies, Inc.). The company sold substantially all assets related to its enterprise 5G solutions business, including rugged handsets and software, to Pace Car Acquisition LLC. Following the transaction, the company changed its name to DNA X, Inc. and intends to pivot its operations to focus on the development and commercialization of an on-chain trading protocol for decentralized exchanges. The company expects to change its trading symbol from SONM to DNAX.
Key Financial Metrics
- Post-Closing Cash: Approximately $6.2 million.
- Debt Repayment: Approximately $5.4 million paid to prepay outstanding promissory notes (the "July Note" and "February Note") to Streeterville Capital, LLC.
- Holdback Amount: $1.5 million retained by the Buyer as security for purchase price adjustments and indemnification obligations.
- Debt Status: All previously disclosed notes to Streeterville Capital, LLC have been terminated.
Material Changes Versus Prior Period
The company has undergone a fundamental transformation in its business model. It has divested its legacy hardware and 5G solutions business, which was its primary revenue generator in prior periods. Consequently, the company's asset base has shifted from physical inventory and manufacturing capabilities to cash and intellectual property related to blockchain trading protocols. The company also resolved a prior Nasdaq listing deficiency regarding the minimum $2.5 million stockholders' equity requirement, believing it has regained compliance as of the filing date.
Guidance, Outlook, and Risks
Outlook: Management intends to utilize the post-closing cash to develop the new on-chain trading protocol. The company anticipates a ticker symbol change to DNAX in the near future.
Risks and Contingencies:
- Holdback Obligations: If purchase price adjustment shortfalls exceed the $1.5 million holdback, the company must pay the excess to the Buyer.
- Listing Compliance: While the company believes it has regained compliance with Nasdaq's stockholders' equity rule, there is no assurance Nasdaq will concur. Failure to maintain compliance could result in delisting.
- Execution Risk: Success depends on the availability of cash to execute the new strategy and the ability to secure the new ticker symbol.
- Contract Consents: The company must obtain specified consents for the assignment of certain contracts within 60 days of closing.
Investor Verification Checklist
- Verify the final approval of the ticker symbol change from SONM to DNAX by Nasdaq.
- Confirm the company's official status regarding Nasdaq listing compliance in subsequent filings.
- Monitor the release of the $1.5 million holdback amount and any potential claims for purchase price adjustments.
- Review the progress of the new on-chain trading protocol development and any associated capital expenditures.
- Check for any unresolved contract assignment consents required within the 60-day post-closing window.